Clinical Trial of Omega-3 Pufa Dietary Supplementation in Patients with Stage 1-3 Breast Cancer

What we are studying

The purpose of this research study is to determine if taking omega-3 polyunsaturated fatty acid (PUFA) supplements affects the levels of omega-3 PUFA in your tumor and in your healthy breast tissue, as well as to determine what effects, good and bad, omega-3 supplements have on your tumor cells.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Women scheduled to undergo surgical removal or newly diagnosed histologically confirmed clinical stage I to III breast carcinoma and carcinoma in situ (including lobular carcinoma in situ and ductal carcinoma in situ)
  • Tumor measurement of at least 1 centimeter on imaging or physical exam
  • Ability to understand and the willingness to sign a written IRB-approved informed consent document
  • No use of any NSAID or full-dose ASA-containing NSAID while taking study drug
  • No use of omega-3 fatty acid supplements within 1 month of enrollment
  • No patients with an allergy or known hypersensitivity to fish

What is involved

  • Randomization into one of the study groups: Taking Omega-3 PUFA supplementation or taking placebo

Compensation

Parking validation

Contact Information

Study Coordinator
Stacey Lewis
Email
stalewis@wakehealth.edu
Phone
336-713-6927
Principal Investigator
Edward Levine, M.D.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.